New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
15:54 EDTBX, CG, DHR, JNJCarlyle in lead to buy J&J ortho clinical diagnostics unit, Reuters says
Johnson & Johnson (JNJ) currently views a bid from Carlyle Group (CG) for its ortho clinical diagnostics unit as superior to a rival bid from Blackstone Group (BX) in partnership with conglomerate Danaher (DHR), three people familiar with the matter said, according to Reuters, which added that the price of Carlyle's offer could not be learned. Reference Link
News For JNJ;CG;BX;DHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 12, 2014
09:16 EDTDHRDanaher price target raised to $93 from $85 at RW Baird
Subscribe for More Information
09:02 EDTBXKimco Realty to buy Blackstone 66.7% share stake in portfolio for $925M
Kimco Realty (KIM) announced that its subsidiary has executed a contract to acquire the remaining 66.667% interest in the 39-property Kimstone portfolio from its joint venture partner, a subsidiary of Blackstone Real Estate Partners VII (BX) for a price of $925M, which includes the assumption of approximately $426.7M in mortgage debt. The company will pay approximately $512.3M to acquire BREP’s interest. Kimco will use a combination of proceeds from recently completed and pending property sales in the U.S. and Latin America as well as availability under its existing $1.75B revolving credit facility to fund this transaction which is expected to be completed in the first quarter of 2015. Upon closing, Kimco will own 100% of the portfolio. The portfolio consists of 39 properties totaling 5.6M square feet and is approximately 97% occupied. The properties in the portfolio are concentrated in the core markets of New York, Virginia, Texas, Florida, California, and Maryland. The portfolio has a three-mile average household income level of $92,000 and an average base rent per square foot of $15.83, both of which exceed Kimco’s current portfolio averages.
08:09 EDTBXBofA/Merrill financial analysts hold an analyst/industry conference call
Banks Analyst Najarian, along with Capital Markets Analyst Carrier, Specialty Finance Analyst Bruce discuss the year ahead in Financials, covering the Banks, Capital Markets, Life and P/C Insurance, REIT, Specialty Finance and Canadian Banks/Life Insurance sectors on an Analyst/Industry conference call to be held on December 16 at 10 am.
07:19 EDTDHRDanaher priced target raised to $94 from $88 at BofA/Merrill
Subscribe for More Information
December 11, 2014
07:49 EDTBXThe New York Times to hold a conference
Subscribe for More Information
07:21 EDTBXShell starts sale process for Tongyi JV stake, WSJ reports
Royal Dutch Shell (RDS.A) has started the sale process for 75% its stake in a Chinese oil lubricants business in a deal that could fetch up to $500M, The Wall Street Journal reports, citing sources. Blackstone (BX) is in a "strong" position in first round bids for the Tongyi oil lubricants joint venture, the sources say. Reference Link
06:04 EDTDHRDanaher sees FY15 adjusted EPS $4.35-$4.45, consensus $4.01
Subscribe for More Information
06:02 EDTDHRDanaher backs Q4 EPS view of $1.00-$1.04, consensus $1.02
05:54 EDTBXBlackstone implied volatility of 23 at lower end of index mean range
Subscribe for More Information
December 9, 2014
13:45 EDTDHRDanaher to host investor and analyst meeting
Subscribe for More Information
07:45 EDTBXGoldman to hold a conference
U.S. Financial Services Conference is being held in New York on December 9-10.
06:33 EDTCGCarlyle Group acquires majority stake in Newgen KnowledgeWorks for $32.8M
The Carlyle Group has invested $32.8M to acquire a 54.85% stake in Chennai, India-based Newgen KnowledgeWorks Private Limited, a provider of publishing and technical services for many of the world’s largest and most prestigious publishers, particularly in the USA, the UK and Europe. Equity for the transaction comes from First Carlyle Ventures III, an investment fund advised by The Carlyle Group. Carlyle acquired the stake held by Franklin Templeton Private Equity Strategy, Aureos South Asia Fund and ePlanet Capital in Newgen. Carlyle had earlier invested in Newgen in 2004 and exited its investment in 2011.
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
08:05 EDTBXHudson Pacific to acquire EOP portfolio from Blackstone for $3.5B
Subscribe for More Information
07:53 EDTDHRDanaher price target raised to $100 from $89 at Jefferies
Jefferies raised its price target for Danaher shares to $100 ahead of the company's investor day and keeps a Buy rating on the name. It expects an initial 2015 organic growth outlook of 3% and earnings guidance of $3.95 and ex-amortization $4.40. Jefferies keeps a Buy rating on the stock.
07:24 EDTBXBlackstone to sell $3.5B of California properties to Hudson Pacific, WSJ says
Subscribe for More Information
06:15 EDTBXBlackstone implied volatility of 21 at lower end of index mean range
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use